CytoDyn secures $30M equity funding commitment from Yorkville Advisors over 36 months

CytoDyn Inc.

Up to $30M in common stock sales to Yorkville over 36 months; company controls timing, no minimum draws.
Shares priced at 98% of lowest 3-day VWAP; Yorkville capped at 4.99% beneficial ownership.
Commitment fee of 1% paid in shares (half immediately, half at 6 months); structuring fee $25k.
Proceeds for working capital, debt repayment, and leronlimab PD-L1 program development.
No warrants or derivatives; registration statement to be filed for resale.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

CytoDyn Inc. issued shares of Common Stock, $0.001 par value per share of common stock to YA II PN, Ltd. (Yorkville) for 98% of the lowest daily VWAP during the three consecutive trading days.

Security: common stock
Shares: shares of Common Stock, $0.001 par value per share
Purchaser: YA II PN, Ltd. (Yorkville)
Consideration: 98% of the lowest daily VWAP during the three consecutive trading days

Exact text from the filing

from the Company, shares of the Company’s common stock, $0.001 par value per share (“Common Stock”). At the Company’s option, the shares of Common Stock would be purchased at 98% of the lowest daily VWAP (as defined below) during the three consecutive trading days (the “Pricing Period”) commencing on the date (each, an “Advance Notice Date”) the Company

View on SEC.gov

Browse all equity issuances →

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-105306

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.